In:
Cancer, Wiley, Vol. 120, No. 9 ( 2014-05), p. 1353-1360
Abstract:
This study is the first to prospectively evaluate whether plasma Epstein‐Barr virus (EBV) DNA load may serve as a complementary screening tool to distinguish nasopharyngeal carcinoma (NPC) patients from the individuals who are positive for anti‐EBV antibodies in a population‐based NPC screening trial in endemic areas. The results provide high‐grade evidence that EBV DNA could be useful in clinical diagnosis of NPC but has limited value in screening for early stage NPC or predicting NPC development.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink